Cellectar biosciences provides update on clover-2 phase 1 clinical trial of iopofosine i 131 in pediatric patients with relapsed/refractory high-grade glioma

In patients receiving a minimum of 55 mci an average 5.4 months of pfs was observed: twice the reported 2.25 median in patients receiving a minimum of 55 mci an average 5.4 months of pfs was observed: twice the reported 2.25 median
CLRB Ratings Summary
CLRB Quant Ranking